Clinical Trial Update: Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tislelizumab with induction chemotherapy for larynx preservation in resectable advanced laryngeal/hypopharyngeal cancer; currently NOT_…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypopharyngeal Cancer
• Laryngeal Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Laryngeal Cancer, Hypopharynx Cancer | Phase 2 | Status: NOT_YET_RECRUITING